Scholarlink

Introduction <p>GLP-1 receptor agonists (GLP-1RAs) are increasingly prescribed for management of obesity and diabetes. In this context, we aim to determine the effect of preoperative GLP-1RA use on surgical outcomes and long-term weight loss following bariatric surgery.</p> Methods <p>We retrospectively identified diabetic patients undergoing primary bariatric surgery at an academic institution between 2014 and 2024. Patients on a GLP-1RA at the time of surgery were compared with GLP-1RA naive patients. Pearson’s chi-squared and Fisher’s exact tests were used where appropriate to compare the differences in baseline characteristics. A 1:1 nearest neighbor propensity match was used to assess the differences in postoperative outcomes. Mixed-effects models were created to account for repeated weight measures postoperatively with the interactions of GLP-1RA therapy on percent total body weight loss (%TBWL). These models were adjusted for procedure type, patient age, sex, and race.</p> Results <p>323 patients met the inclusion criteria. 132 (40.9%) patients were on a GLP-1RA at the time of their procedure while 191 (59.1%) were not. On univariate comparison, GLP-1RA naive patients were less likely to have hyperlipidemia (57% v 69%, p = 0.03) and more likely to undergo RYGB than GLP-1RA patients (84.82% vs 62.88%, p &lt; 0.001). There were no differences in any 30-day postoperative outcomes. GLP-1RA naive patients had better weight loss at one year postoperatively than GLP-1RA patients (TBWL 24.1% vs 20.5%, p = .003). As the follow-up period extended, the weight loss between the groups became more similar. At 5&#xa0;years postoperatively, the GLP-1RA naive patients had 19.8% TBWL vs. 19.4% TBWL in the GLP-1RA group (p = 0.80).</p> Conclusions <p>Preoperative GLP-1RA use is safe prior to bariatric surgery but is associated with inferior early postoperative weight loss in diabetic patients. GLP-1RA naive patients appear to experience greater weight recidivism when compared to patients on a GLP-1RA prior to surgery, resulting in comparable long-term weight loss.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of preoperative glucagon-like peptide-1 receptor agonist therapy on weight loss following bariatric surgery

  • 期刊论文

  • 发表日期：

    2025年6月9日

查看全文
  • Mason Friesch,
  • Mitchel Fernando,
  • Emma Sheedy,
  • Irena Helenowski,
  • Laura Wool,
  • Monica Edwards,
  • Kevin Brown,
  • James Lau,
  • Tyler Cohn

摘要

Introduction

GLP-1 receptor agonists (GLP-1RAs) are increasingly prescribed for management of obesity and diabetes. In this context, we aim to determine the effect of preoperative GLP-1RA use on surgical outcomes and long-term weight loss following bariatric surgery.

Methods

We retrospectively identified diabetic patients undergoing primary bariatric surgery at an academic institution between 2014 and 2024. Patients on a GLP-1RA at the time of surgery were compared with GLP-1RA naive patients. Pearson’s chi-squared and Fisher’s exact tests were used where appropriate to compare the differences in baseline characteristics. A 1:1 nearest neighbor propensity match was used to assess the differences in postoperative outcomes. Mixed-effects models were created to account for repeated weight measures postoperatively with the interactions of GLP-1RA therapy on percent total body weight loss (%TBWL). These models were adjusted for procedure type, patient age, sex, and race.

Results

323 patients met the inclusion criteria. 132 (40.9%) patients were on a GLP-1RA at the time of their procedure while 191 (59.1%) were not. On univariate comparison, GLP-1RA naive patients were less likely to have hyperlipidemia (57% v 69%, p = 0.03) and more likely to undergo RYGB than GLP-1RA patients (84.82% vs 62.88%, p < 0.001). There were no differences in any 30-day postoperative outcomes. GLP-1RA naive patients had better weight loss at one year postoperatively than GLP-1RA patients (TBWL 24.1% vs 20.5%, p = .003). As the follow-up period extended, the weight loss between the groups became more similar. At 5 years postoperatively, the GLP-1RA naive patients had 19.8% TBWL vs. 19.4% TBWL in the GLP-1RA group (p = 0.80).

Conclusions

Preoperative GLP-1RA use is safe prior to bariatric surgery but is associated with inferior early postoperative weight loss in diabetic patients. GLP-1RA naive patients appear to experience greater weight recidivism when compared to patients on a GLP-1RA prior to surgery, resulting in comparable long-term weight loss.